Tumor Biology

, Volume 37, Issue 1, pp 199–200 | Cite as

Note of the methodological flaws in the paper entitled “Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis”



With great interest, we read the paper “Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis” (by Chen PQ et al.) [1], which has reached important conclusions about the relationship between polymorphisms in interleukin (IL)-4/IL-13 pathway genes and glioma risk. Through quantitative analysis, the meta-analysis found no association between IL-4/IL-13 pathway genetic polymorphisms and glioma risk (Chen et al. in Tumor Biol 36:121–127, 2015). The meta-analysis is the most comprehensive study of polymorphisms in the IL-4/IL-13 pathway and glioma risk. Nevertheless, some deficiencies still exist in this meta-analysis that we would like to raise.


IL-4/IL-13 Glioma Polymorphisms Meta-analysis 


Compliance with ethical standards

Conflicts of interest



  1. 1.
    Chen PQ, Chen C, Luo C, et al. Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis. Tumor Biol. 2015;36:121–7.CrossRefGoogle Scholar
  2. 2.
    Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, AlMadhani A, Ganguly SS, et al. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric Cancer. 2006;9(4):284–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, et al. RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat. 2011;125(3):827–35.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Neurology, West China HospitalSichuan UniversityChengduChina

Personalised recommendations